ArticleRheumatology (Oxford, England)2020
Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.
Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2025Article
- Recent advances and evolving concepts in Still's disease.Nature reviews. Rheumatology · 2024Review
- [Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
- Observational
- A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still's Disease: A Single-Center Retrospective Observational Study.Rheumatology and therapy · 2023Article
- Adult-onset Still's disease in Western Australia: Epidemiology, comorbidity and long-term outcome.International journal of rheumatic diseases · 2022Article
- Evaluation of Glycosylated Ferritin in Adult-Onset Still's Disease and Differential Diagnoses.Journal of clinical medicine · 2022Article
- Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings.Rheumatology and therapy · 2022Article
- Latent class analysis of 216 patients with adult-onset Still's disease.Arthritis research & therapy · 2022Article
- Detection and Prediction of Macrophage Activation Syndrome in Still's Disease.Journal of clinical medicine · 2021Article
- Efficacy of tight control strategy in the treatment of adult-onset Still disease.Clinical rheumatology · 2021Article
- Recurrent deep venous thromboses in a patient with adult-onset Still's disease.BMJ case reports · 2021Article
- Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.Expert opinion on biological therapy · 2020Article
- Comment on: Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database: reply.Rheumatology (Oxford, England) · 2020Article
- The Role of Sex and Gender in Dermatology - From Pathogenesis to Clinical Implications.Journal of cutaneous medicine and surgeryReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
objectivesWe aimed to describe clinical characteristics, treatment patterns and major comorbidities of a US-based adult-onset Still's disease (AOSD) cohort.
methodsAdministrative claims data from Truven MarketScan were collected from 2009 to 2015. An AOSD case was defined as ≥1 M06.1 International Classification of Diseases 10th revision (ICD-10) medical claim code. We extracted data for the AOSD cohort (n = 106) and 1:5 matched controls (n = 530) without AOSD. Outcomes of interest and a novel claims-based set of Yamaguchi criteria were identified by relevant ICD 9th revision (ICD-9) and ICD-10 codes. Bivariate descriptive analyses were conducted on all variables. Comorbidity rates and rate ratios were calculated in AOSD cases and matched controls. Statistical significance of cohort differences was determined to compare AOSD cases and matched controls.
resultsThe AOSD cohort, with a mean age of 43.08 (standard deviation, s.d. 13.9) years and with female predominance (68.9%) was observed over a mean of 750.12 (637.6) days. A total of 35.9% of AOSD patients fulfilled claims-based Yamaguchi criteria compared with 0.4% matched controls (P< 0.05). We identified severe AOSD-related complications, including macrophage activation syndrome (4.7%) and acute respiratory distress syndrome (12.3%). Treatment commonly involved systemic glucocorticoids (62.2%), MTX (51%) and anakinra (24.5%). Compared with matched controls, serious infections were significantly increased (rate ratio 2.58, 95% CI: 1.53, 4.37, P = 0.0004), while hyperlipidaemia (0.54, 95% CI: 0.35, 0.85; P = 0.008) and obesity (0.30, 95% CI: 0.15, 0.62; P = 0.001) were significantly decreased in AOSD patients.
conclusionWe characterized a first US-based AOSD cohort using a large national administrative claims database, and identified key complications, treatments and comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.